Guest Speaker

David Walk, MD FAAN
University of Minnesota, MN
Platform Trial Site Investigator
University of Minnesota Platform Trial Staff

David Walk  
Site Investigator

Valerie Ferment  
Research Coordinator

Sam Maiser  
Site Co-Investigator

Sarah Hilbert  
Research Manager

Cat Koukol  
Research Coordinator

Carly Schroeder  
Research Coordinator/Evaluator
Twin Cities ALS Research Consortium
Perpetual Adaptive Trial
Shared Placebo; Randomization Ratio 3:1
Open Label Extension (OLE) offered

Regimen A (n=160 for each regimen)
Regimen B
Regimen C
Regimen D (n=120 for active; n=40 for placebo)

3:1 Randomization within each Regimen

Zilucoplan
Verdiperstat
CNM-Au8
Pridopidine
Shared Placebo

Open Label Extension

Up to 6 weeks
24 weeks (about 6 months)

Informed Consent
Assign to Regimen
Randomize within Regimen (active/placebo)
Open Label Extension
Enrollment Updates (as of October 14, 2021)

• 803 individuals with ALS signed informed consent
• 636 individuals were assigned to a regimen
• 571 individuals were randomized within a regimen (active or placebo)
• 230 have entered the Open Label Extension (OLE)

• 155 individuals were randomized within Regimen A = 162
• 167 individuals were randomized within Regimen B = 167
• 161 individuals were randomized within Regimen C = 161
• 88 individuals were randomized within Regimen D = 109

Thank You
This breakthrough trial would not be possible without your partnership
How to Find a Center Near You

52 sites are actively enrolling

Contact Info of Participating Sites by State

https://www.massgeneral.org/neurology/als/research/platform-trial-sites
Patient Navigator

Catherine Small
Allison Bulat
Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

To see whether you might qualify, view the list of eligibility criteria:
Send us webinar ideas!

- Biomarkers
- Biostatistics / Trial Design
- Get to know our sites

Upcoming Guest Speakers:
Oct 21st - Xiaowei (Bill) Su, MD, PhD (Penn State Health, PA)
Oct 28th - Megan Miller, PhD (IAMALS Director of Science and Policy)